

Date: February 27, 2026

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051
Maharashtra, India.

Symbol: FABTECH

BSE Limited

Listing Department
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India.

Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation Investors/Analysts Meeting, CVOCA Investocraft 2026, to be held on February 28, 2026 from 8:30 a.m. (IST) onwards.

Request you to take the same on record.

Thank you.

Yours faithfully,
For Fabtech Technologies Limited

Hemant Mohan Anavkar
Executive Director
DIN: 00150776

Encl.: As mentioned above



Fabtech[®]
Technologies Limited
Life Engineering[™]


India's Global Life Sciences Infrastructure Platform

Engineering Medicinal Sovereignty Across Continents

Medicinal Sovereignty is driving a 15-year Lifescience infrastructure buildout across GCC, Middle East & Africa and surrounding nations.

Fabtech is positioned as:

			
Design & Build-led	Diversified dosage form portfolio	Local execution presence	Policy-aligned infrastructure partner



Execution Strength

Integrated capabilities:



Process Engineering

End-to-end process design and engineering expertise.



Water (WFI, PW, PS systems)

Water for Injection and Purified Water systems.



Air (HVAC, containment)

Cleanroom HVAC and containment systems.



In-house manufacturing leverage

Controlled execution platform – not just an EPC.

Our ecosystem



Total Addressable Market (TAM)

GCC Market

(UAE, KSA, Qatar, Oman, Kuwait, Bahrain)

Estimated Pharma Capex
(2025–2040):

USD 40–50 Billion

- Drivers:
- Saudi Vision 2030
- UAE biotech & vaccine push
- Localization mandates
- Oncology & biosimilars manufacturing

Maghreb

(Algeria, Morocco, Tunisia, Libya)

Estimated Pharma Capex
(2025–2040):

USD 15–20 Billion

- Drivers:
- EU supply chain diversification
- Generics independence
- Biotech migration from Europe

Africa

(Egypt, Ethiopia, Kenya, Nigeria + emerging)

Estimated Pharma Capex
(2025–2040):

USD 60–70 Billion

- Drivers:
- Vaccine independence
- WHO regional manufacturing hubs
- API backward integration
- Animal health & biologics expansion

Total Addressable Pharma Infrastructure Market

Total Addressable Pharma Infrastructure Market **2025–2040** Estimate **USD 115 – 140 Billion** (₹9.5 – 11.5 Lakh Crore equivalent)

Even **2–3%** capture = transformational scale.

Source: Grand View Research (Pharmaceutical Manufacturing Market Report), [inferred regional capex estimates]

Why This is a 15-Year Pipeline

Countries evolve manufacturing capability in stages:

- Oral solids
- Liquids
- Oncology
- Biosimilars
- Packaging
- APIs
- Ointments
- Biotech
- Injectables
- Vaccines

Each stage requires:

Process Engineering

Cleanroom & HVAC Systems

Packaging lines

Water Systems

Validation

Regulatory Integration

This creates repeat infra demand and influence **100%** of compliance outcome

Our Strategic Presence

Geographic Footprint:

UAE operating base

Saudi footprint

References in Africa

European entity acquisition (technical credibility & conversion lever)

Conversion Rate Growth:

Current conversion


10%

Post-Acquisition Target

20%

Doubling hit rate = exponential growth on same lead base

VALUE CHAIN: ROLE OF A **TURNKEY ENGINEERING** SOLUTION PROVIDER



From Advisory to Post-Compliance Support: Start-to-End Services Covering the Entire Project Value Chain

Proven Benchmark Projects



First Egyptian Flu Vaccine Project



Largest IV Solution Facility – Saudi



First Oncology Project – Saudi



First Biosimilars Facility – Saudi



UAE's Only USFDA Approved Facility

These Create:

Regulatory Credibility

Entry Barriers

Reference Moat

Repeat Pipeline

Order Book & Pipeline

Orders in hand

Current confirmed orders ready for execution in the coming periods.

≈926Cr


As on 31st Jan 26

Conversion Target

Improving conversion rate post-European acquisition for structural visibility.

10% to 20%

Why Fabtech



**We are not building factories.
We are building medicinal sovereignty infrastructure across
continents**



15-year structural opportunity.



Scalable execution model



Reference-led moat.

THANK YOU

Start-to-Finish partner for pharma,
pharma, biotech & healthcare

62+ countries, Experience of
completing 2000+ projects in
different countries

Expertise across Design,
Engineering Installation, &
Certification

In-house manufacturing by
group companies ensure
execution speed

